Cash figures as of 2025-06-30. Database snapshot: 2026-09-22.
Price history
Loading ATHE daily closes…
Loading price history…
Pipeline assets
ATH434
Phase 2 · Active
Target Iron (Fe2+)
Indications
multiple system atrophy (MSA)(Phase 2)
Catalysts
— end of 2026
Status note Lead product candidate; company developing disease-modifying therapies for MSA and other Parkinsonian disorders. Successful End-of-Phase 2 meeting with FDA in June 2026 aligned key elements of registrational Phase 3 program in MSA.
Per-asset detail extracted from the 20-F filed 2026-08-28. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.